TransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting
ANDOVER, Mass., June 10, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the U.S. Food and Drug Administration ("FDA") has announced the scheduling of a public advisory committee meeting during which it will review information regarding TransMedics' premarket approval application for the OCS Liver System. The Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee will meet on on July 14, 2021 to discuss, make recommendations, and vote on a recommendation for approval of the OCS Liver system.
"This is another important milestone to bring TransMedics closer to having all of our three organ platforms approved by FDA in 2021," said Waleed Hassanein, M.D.
"We are looking forward to presenting the OCS Liver PROTECT data to the advisory committee panel in support of our PMA for the OCS Liver System. This is another important milestone to bring TransMedics closer to having all of our three organ platforms approved by FDA in 2021," said Waleed Hassanein, M.D., President and Chief xecutive Officer.
About TransMedics Group, Inc.
View original content to download multimedia:http://www.prnewswire.com/news-releases/transmedics-announces-scheduling-of-ocs-liver-fda-advisory-committee-meeting-301310185.html
SOURCE TransMedics Group, Inc.
The Cybersecurity Opportunity for MSPs
Keynote Presentation by Zoom
IDEA Showcase Startup Pitch Event & Reception